Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the launch of a research collaboration with Memorial Sloan Kettering Cancer Center (MSK), a premier cancer center committed to patient care and innovative research, to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy.

The goal of the collaboration, titled “MINE™” (My Immunotherapy Neo-Epitopes), is to use Advaxis’s LmTechnology™ to develop neo-epitope immunotherapies based on an individual patient’s tumor (“ADXS-NEO”). MINE™ will first focus on a preclinical study of Advaxis’s new construct approach to evaluate the immunologic effects and anti-tumor activity of a personalized immunotherapy in a mouse tumor model. Advaxis will use learnings from the MINE™ collaboration to identify and target neoepitopes using Lm Technology™ and later develop patient specific immunotherapy constructs that incorporate the neoepitope sequences identified in the patient’s tumor cells. Clinical studies using ADXS-NEO, to be conducted at MSK, are in development.

“Existing immunotherapies have been shown to very effectively augment tumor immunity in a subset of patients, leading to durable responses,” said Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at MSK. “However, recent advances in genome sequencing have made it possible to investigate the role of neoepitopes, or unique mutations, in an individual patient’s cancer, which may allow for the development of specific immunotherapies that generate and enhance an immune response directed against the neoepitopes contained in a patient’s tumor.”

Advaxis’s Lm Technology™ is uniquely positioned to take advantage of the advances in genome sequencing which occurred in recent years. Lm Technology™ has the bandwidth to potentially target all of a patient’s immunogenic cancer neoepitopes, eliminating the need to use “predictive algorithms.” This technology can enable the development of truly individualized immunotherapies that can be manufactured in a cost-effective and timely manner.

“We welcome this collaboration with MSK, a top cancer institution, which will allow us to study our clinically validated Lm Technology™ in a new way to deliver precision medicine by personalizing neoepitopes specific to a patient’s tumor,” said David J. Mauro, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Advaxis.  (Original Source)

Shares of Advaxis Inc closed yesterday at $11.09. ADXS has a 1-year high of $30.13 and a 1-year low of $2.68. The stock’s 50-day moving average is $12.94 and its 200-day moving average is $17.61.

On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on October 5, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on ADXS, with a price target of $30, which represents a potential upside of 170.5% from where the stock is currently trading. Separately, on August 7, FBR’s Vernon Bernardino initiated coverage with a Buy rating on the stock and has a price target of $34.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Swayampakula Ramakanth and Vernon Bernardino have a total average return of -18.2% and -20.9% respectively. Ramakanth has a success rate of 16.7% and is ranked #3757 out of 3802 analysts, while Bernardino has a success rate of 22.5% and is ranked #3780.

Advaxis Inc is a clinical development stage biotechnology company. The company is engaged in developing safe & effective immunotherapies for cancer & infectious diseases.